Avadomide monotherapy in relapsed/refractory DLBCL: Safety, efficacy, and a predictive gene classifier.
暂无分享,去创建一个
G. Salles | A. Salar | J. Sancho | R. Bouabdallah | A. Weng | M. Trotter | A. Santoro | F. Schmitz | D. Rasco | G. Verhoef | P. Hagner | S. Carrancio | L. Ysebaert | J. López-Martín | V. Ribrag | M. Pourdehnad | S. Damian | A. Risueño | C. Panizo | Xuehai Wang | K. Hege | S. Couto | Xin-Xin Wei | C. Carpio | R. Cordoba | Alejandro Martín | M. Gharibo | A. Gandhi | Maria Wang | A. Pinto | E. Van Den Neste | T. J. Buchholz | R. Córdoba
[1] J. Cerhan,et al. Leveraging Gene Expression Subgroups to Classify DLBCL Patients and Enrich for Clinical Benefit to a Novel Agent. , 2020, Blood.
[2] K. Tarte,et al. Combination lenalidomide‐rituximab immunotherapy activates anti‐tumour immunity and induces tumour cell death by complementary mechanisms of action in follicular lymphoma , 2019, British journal of haematology.
[3] Juliet Investigators. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma , 2019 .
[4] A. López-Guillermo,et al. Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[5] K. Papadopoulos,et al. A First-in-Human Study of Novel Cereblon Modulator Avadomide (CC-122) in Advanced Malignancies , 2018, Clinical Cancer Research.
[6] Stefano Monti,et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes , 2018, Nature Medicine.
[7] Roland Schmitz,et al. Genetics and Pathogenesis of Diffuse Large B‐Cell Lymphoma , 2018, The New England journal of medicine.
[8] Jing Fu,et al. IMiD compounds affect CD34+ cell fate and maturation via CRBN-induced IKZF1 degradation. , 2018, Blood advances.
[9] M. Trotter,et al. Activity of lenalidomide in mantle cell lymphoma can be explained by NK cell‐mediated cytotoxicity , 2017, British journal of haematology.
[10] J. Cerhan,et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. , 2017, Blood.
[11] J. Cerhan,et al. Clinical heterogeneity of diffuse large B cell lymphoma following failure of front‐line immunochemotherapy , 2017, British journal of haematology.
[12] A. Rosenwald,et al. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] L. Staudt,et al. A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma , 2017, Clinical Cancer Research.
[14] N. Nishimura,et al. Low absolute peripheral blood CD4+ T-cell count predicts poor prognosis in R-CHOP-treated patients with diffuse large B-cell lymphoma , 2017, Blood Cancer Journal.
[15] J. Cerhan,et al. Associations between elevated pre‐treatment serum cytokines and peripheral blood cellular markers of immunosuppression in patients with lymphoma , 2017, American journal of hematology.
[16] Kengo Takeuchi,et al. Low absolute peripheral blood CD4+ T-cell count predicts poor prognosis in R-CHOP-treated patients with diffuse large B-cell lymphoma , 2017, Blood cancer journal.
[17] J. Caldwell,et al. Chemical approaches to targeted protein degradation through modulation of the ubiquitin–proteasome pathway , 2017, The Biochemical journal.
[18] T. Marafioti,et al. Does cell-of-origin or MYC, BCL2 or BCL6 translocation status provide prognostic information beyond the International Prognostic Index score in patients with diffuse large B-cell lymphoma treated with rituximab and chemotherapy? A systematic review , 2017, Leukemia & lymphoma.
[19] N. Schmitz,et al. Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study , 2017, Bone Marrow Transplantation.
[20] Bingshu E. Chen,et al. Effect of the addition of rituximab to salvage chemotherapy prior to autologous stem cell transplant in aggressive CD20+ lymphoma: a cohort comparison from the NCIC Clinical Trials Group Study LY.12* , 2017, Leukemia & lymphoma.
[21] A. Klippel,et al. CC-122 Exhibits Greater Preclinical Activity in Mantle Cell Lymphoma Than Lenalidomide through a Combination of Direct Cell-Autonomous and Increased Antibody Dependent Cell-Mediated Cytotoxicity , 2016 .
[22] J. Cerhan,et al. 2016 US lymphoid malignancy statistics by World Health Organization subtypes , 2016, CA: a cancer journal for clinicians.
[23] B. Nathwani,et al. Non-Hodgkin lymphoma in the developing world: review of 4539 cases from the International Non-Hodgkin Lymphoma Classification Project , 2016, Haematologica.
[24] Michael R. Green,et al. The T-cell Receptor Repertoire Influences the Tumor Microenvironment and Is Associated with Survival in Aggressive B-cell Lymphoma , 2016, Clinical Cancer Research.
[25] R. Advani,et al. The World Health Organization Classification of Lymphoid Neoplasms , 2013 .
[26] N. Schmitz,et al. Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study , 2016, Bone Marrow Transplantation.
[27] J. Sancho,et al. CC-122 Dosing on a Novel Intermittent Schedule Mitigates Neutropenia and Maintains Clinical Activity in Subjects with Relapsed or Refractory Diffuse Large B Cell Lymphoma , 2015 .
[28] P. Hassa,et al. Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review , 2015, Molecular Cancer.
[29] Michael R. Green,et al. Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study. , 2015, The Lancet. Haematology.
[30] A. Klippel,et al. Rate of CRL4CRBN substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4 , 2015, Blood Cancer Journal.
[31] M. Trotter,et al. CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL. , 2015, Blood.
[32] L. Staudt,et al. Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] Roland Schmitz,et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma , 2015, Nature Medicine.
[34] R. Gascoyne,et al. Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] R. Gascoyne,et al. Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity. , 2015, Blood.
[36] Bingshu E. Chen,et al. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] H. Handa,et al. Structure of the human Cereblon–DDB1–lenalidomide complex reveals basis for responsiveness to thalidomide analogs , 2014, Nature Structural &Molecular Biology.
[38] H. Handa,et al. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4CRBN , 2013, British journal of haematology.
[39] R. Chopra,et al. A First In Human Dose Escalation Study Of CC-122, A First-In-Class Pleiotropic Pathway Modulator™ (PPM) Compound In Subjects With Relapsed Or Refractory Solid Tumors, Multiple Myeloma and Non-Hodgkin’s Lymphoma , 2013 .
[40] R. Emerson,et al. Using synthetic templates to design an unbiased multiplex PCR assay , 2013, Nature Communications.
[41] M. Gandhi,et al. CD4+ Tumor infiltrating lymphocytes are prognostic and independent of R‐IPI in patients with DLBCL receiving R‐CHOP chemo‐immunotherapy , 2013, American journal of hematology.
[42] R. Chopra,et al. Lenalidomide efficacy in activated B‐cell‐like subtype diffuse large B‐cell lymphoma is dependent upon IRF4 and cereblon expression , 2012, British journal of haematology.
[43] N. Schmitz,et al. Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[44] S. Karasawa,et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide , 2012, Leukemia.
[45] J. Blay,et al. Lymphopenia combined with low TCR diversity (divpenia) predicts poor overall survival in metastatic breast cancer patients , 2012, Oncoimmunology.
[46] S. Karasawa,et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide , 2012, Leukemia.
[47] A. Rosenwald,et al. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[48] F. Berrino,et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. , 2010, Blood.
[49] N. Schmitz,et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[50] Toshihiko Ogura,et al. Identification of a Primary Target of Thalidomide Teratogenicity , 2010, Science.
[51] D. de Jong,et al. Inflammatory cells and immune microenvironment in malignant lymphoma , 2008, Journal of internal medicine.
[52] L. Staudt,et al. Stromal gene signatures in large-B-cell lymphomas. , 2008, The New England journal of medicine.
[53] P. Bendahl,et al. Genes associated with the tumour microenvironment are differentially expressed in cured versus primary chemotherapy‐refractory diffuse large B‐cell lymphoma , 2008, British journal of haematology.
[54] Sigrid Stroobants,et al. Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[55] Pablo Tamayo,et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[56] T. Golub,et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. , 2004, Blood.
[57] L. Staudt,et al. Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. , 2004, Blood.
[58] L. Staudt,et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.
[59] Meland,et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.
[60] Ash A. Alizadeh,et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.
[61] A. Hagenbeek,et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. , 1995, The New England journal of medicine.